Clinical trials
Angina Pectoris trials in the United States with no applicable phase
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
30 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2003 | 1 |
| 2004 | 1 |
| 2006 | 1 |
| 2007 | 1 |
| 2008 | 1 |
| 2010 | 2 |
| 2011 | 3 |
| 2013 | 1 |
| 2014 | 3 |
| 2015 | 2 |
| 2017 | 2 |
| 2019 | 1 |
| 2021 | 2 |
| 2022 | 2 |
| 2023 | 2 |
| 2024 | 1 |
| 2025 | 2 |
| 2026 | 2 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 17 |
| Recruiting | 5 |
| Terminated | 3 |
| Active, not recruiting | 2 |
| Not yet recruiting | 1 |
| Suspended | 1 |
| Unknown status | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Montefiore Medical Center | 3 |
| University of Virginia | 2 |
| Abbott Medical Devices | 1 |
| BioCardia, Inc. | 1 |
| Biotronik, Inc. | 1 |
| Columbia University | 1 |
| Corewell Health East | 1 |
| Duke University | 1 |
| Emory University | 1 |
| Haukeland University Hospital | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Angina Pectoris | 30 |
| Coronary Artery Disease | 13 |
| Chest Pain | 7 |
| Acute Coronary Syndrome | 6 |
| Cardiovascular Diseases | 5 |
| Myocardial Ischemia | 5 |
| Angina, Stable | 4 |
| Coronary Disease | 4 |
| Angina, Unstable | 3 |
| Heart Diseases | 3 |
Trials
Showing 1 to 25 of 30. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.